ArticleBMC research notes2026
Use of noninvasive positive pressure ventilation in patients admitted to the internal medicine service of a tertiary care hospital.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNoninvasive positive pressure ventilation (NIPPV) is commonly used in acute respiratory failure but is often applied outside evidence-based indications, particularly in low- and middle-income countries. Our objective is to assess the appropriateness of NIPPV use among internal medicine patients at a tertiary hospital in Pakistan. Appropriate use was defined as Type 1 or Type 2 respiratory failure, cardiogenic pulmonary edema, or chest wall/neuromuscular disease. Inappropriate use was defined as NIPPV applied outside standard indications.
resultsWe conducted a cross-sectional study on 4369 patients who received NIPPV between 2019 and 2020 in the Internal Medicine unit at the Aga Khan University Hospital, Karachi. The mean age was 62.7 years, and 52.4% were male. Overall, 60.5% received NIPPV without documented respiratory failure, 21.5% had Type 1, and 18% had Type 2 failure. Metabolic acidosis accounted for 19.6% of inappropriate cases. Among Type 1 failure, pneumonia (43.1%), pulmonary edema (35.3%), and COPD (6.2%) were most common; in Type 2 failure, pulmonary edema (37.7%), pneumonia (25.8%), and COPD (15.1%) predominated. NIPPV was appropriately used in COPD and acute cardiogenic pulmonary edema but frequently applied outside evidence-based indications, particularly for metabolic acidosis. Structured protocols and research are needed on NIPPV use in LMICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.